Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Cellectis S.A.
  6. Summary
    ALCLS   FR0010425595

CELLECTIS S.A.

(ALCLS)
  Report
Real-time Euronext Paris  -  04:43 2022-08-10 am EDT
3.162 EUR   -1.50%
08/09European ADRs Move Higher in Tuesday Trading
MT
08/08European ADRs Move Higher in Monday Trading
MT
08/05European ADRs Move Lower in Friday Trading
MT
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Real-time Quote. Real-time Euronext Paris
08/04/2022 08/05/2022 08/08/2022 08/09/2022 08/10/2022 Date
2.988(c) 3.27(c) 3.56(c) 3.21(c) 3.162 Last
315 140 272 577 356 613 380 668 71 150 Volume
-6.80% +9.44% +8.87% -9.83% -1.50% Change
More quotes
Estimated financial data (e)
Sales 2022 42,6 M 43,5 M 43,5 M
Net income 2022 -97,5 M -99,7 M -99,7 M
Net Debt 2022 0,50 M 0,51 M 0,51 M
P/E ratio 2022 -0,89x
Yield 2022 -
Sales 2023 55,0 M 56,2 M 56,2 M
Net income 2023 -124 M -127 M -127 M
Net Debt 2023 59,0 M 60,3 M 60,3 M
P/E ratio 2023 -0,90x
Yield 2023 -
Capitalization 146 M 149 M 149 M
EV / Sales 2022 3,44x
EV / Sales 2023 3,73x
Nbr of Employees 297
Free-Float 99,9%
More Financials
Company
Cellectis S.A. is developing the first of its kind allogeneic approach for CAR-T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients. As a clinical-stage biopharmaceutical company with over 22 years of expertise in gene editing, Cellectis S.A. is developing life-changing product candidates utilizing TALEN®, its gene editing... 
Read more
More about the company
Ratings of Cellectis S.A.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C
More Ratings
All news about CELLECTIS S.A.
08/09European ADRs Move Higher in Tuesday Trading
MT
08/08European ADRs Move Higher in Monday Trading
MT
08/05European ADRs Move Lower in Friday Trading
MT
08/05TRANSCRIPT : Cellectis S.A., Q2 2022 Earnings Call, Aug 05, 2022
CI
08/04CELLECTIS S A : PRELIMINARY NOTE - Form 6-K
PU
08/04CALYXT : Q2 Earnings Snapshot
AQ
08/04CELLECTIS S A : Provides Business Update and Reports Financial Results for Second Quarter ..
PU
08/04CELLECTIS S A : Provides Business Update and Reports Financial Results for Second Quarter ..
PU
08/04CALYXT, INC. Management's Discussion and Analysis of Financial Condition and Results o..
AQ
08/04Cellectis S.A. Reports Earnings Results for the Second Quarter and Six Months Ended Jun..
CI
08/04Cellectis S.A. Announces Executive Changes
CI
08/04Cellectis Provides Business Update and Reports Financial Results for Second Quarter 202..
GL
08/04European ADRs Move Higher in Thursday Trading
MT
08/04CELLECTIS S.A. : Half-year results
CO
08/03European ADRs Nudge Higher in Wednesday Trading
MT
More news
News in other languages on CELLECTIS S.A.
08/09Les ADR européens sont en hausse mardi
08/08Les ADR européens progressent lundi
08/05Les ADR européens sont en baisse vendredi
08/05CELLECTIS : activités financées jusqu'à début 2024
08/04Cellectis S.A. annonce ses résultats pour le deuxième trimestre et le semestre clos le ..
More news
Analyst Recommendations on CELLECTIS S.A.
More recommendations
Chart CELLECTIS S.A.
Duration : Period :
Cellectis S.A. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CELLECTIS S.A.
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Last Close Price 3,21 €
Average target price 10,60 €
Spread / Average Target 230%
EPS Revisions
Managers and Directors
André Choulika Chief Executive Officer & Director
Bing C. Wang Chief Financial Officer
Jean-Pierre Garnier Non-Executive Chairman
Philippe Duchateau Chief Scientific Officer
Carrie Brownstein Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
CELLECTIS S.A.-56.85%149
MODERNA, INC.-32.62%71 566
LONZA GROUP AG-26.08%43 806
IQVIA HOLDINGS INC.-17.18%43 579
SEAGEN INC.13.58%32 890
ALNYLAM PHARMACEUTICALS, INC.31.72%27 695